226 related articles for article (PubMed ID: 32940635)
1. Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee.
Patel MM; Thornburg NJ; Stubblefield WB; Talbot HK; Coughlin MM; Feldstein LR; Self WH
JAMA; 2020 Nov; 324(17):1781-1782. PubMed ID: 32940635
[TBL] [Abstract][Full Text] [Related]
2. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
Prus K; Alquist CR; Cancelas JA; Oh D
Transfusion; 2021 Feb; 61(2):651-654. PubMed ID: 33616966
[No Abstract] [Full Text] [Related]
3. Antibodies, epicenter of SARS-CoV-2 immunology.
Pecetta S; Pizza M; Sala C; Andreano E; Pileri P; Troisi M; Pantano E; Manganaro N; Rappuoli R
Cell Death Differ; 2021 Feb; 28(2):821-824. PubMed ID: 33500559
[No Abstract] [Full Text] [Related]
4. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
[No Abstract] [Full Text] [Related]
5. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19-Nashville, Tennessee.
Stubblefield WB; Talbot HK; Feldstein LR; Tenforde MW; Ur Rasheed MA; Mills L; Lester SN; Freeman B; Thornburg NJ; Jones ID; Ward MJ; Lindsell CJ; Baughman A; Halasa N; Grijalva CG; Rice TW; Patel MM; Self WH
Clin Infect Dis; 2021 May; 72(9):1645-1648. PubMed ID: 32628750
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Pandemic and Virtual Clinics for Diabetes Care.
Garg SK; Reinicke T
Diabetes Technol Ther; 2021 Jun; 23(S2):S3-S15. PubMed ID: 34061640
[No Abstract] [Full Text] [Related]
8. Global virus tracker.
Powell K
Nature; 2021 May; 593(7857):160. PubMed ID: 33941925
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
Laterza R; Schirinzi A; Bruno R; Genco R; Contino R; Ostuni A; Di Serio F
Eur J Clin Invest; 2021 Jul; 51(7):e13573. PubMed ID: 33870493
[No Abstract] [Full Text] [Related]
10. Thinking more about therapy with convalescent plasma for COVID-19 patients.
Han G; Zhou YH
Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
[No Abstract] [Full Text] [Related]
11. Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam.
Chau NVV; Toan LM; Man DNH; Thao HP; Lan NPH; Ty DTB; Hieu DK; Tien NTM; Ngoc NM; Hung LM; Dung NT; Thanh TT; Truong NT; Thwaites G; Tan LV
J Infect; 2021 Jan; 82(1):e36-e37. PubMed ID: 33221367
[No Abstract] [Full Text] [Related]
12. Seroprevalence to SARS-CoV-2 Among Healthcare Workers in an Exclusive Pediatric Hospital.
Madhusudan M; Sankar J; Dhanalakshmi K; Putlibai S; Balasubramanian S
Indian Pediatr; 2021 Mar; 58(3):279-280. PubMed ID: 33713065
[No Abstract] [Full Text] [Related]
13. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
[No Abstract] [Full Text] [Related]
14. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
[TBL] [Abstract][Full Text] [Related]
15. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.
Zeng F; Dai C; Cai P; Wang J; Xu L; Li J; Hu G; Wang Z; Zheng F; Wang L
J Med Virol; 2020 Oct; 92(10):2050-2054. PubMed ID: 32383183
[TBL] [Abstract][Full Text] [Related]
16. Convalescent plasma to treat COVID-19: clinical experience and efficacy.
Pei S; Yuan X; Zhang Z; Yao R; Xie Y; Shen M; Li B; Chen X; Yin M
Aging (Albany NY); 2021 Mar; 13(6):7758-7766. PubMed ID: 33735836
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study.
Brehm TT; Schwinge D; Lampalzer S; Schlicker V; Küchen J; Thompson M; Ullrich F; Huber S; Schmiedel S; Addo MM; Lütgehetmann M; Knobloch JK; Schulze Zur Wiesch J; Lohse AW
Int J Hyg Environ Health; 2021 Mar; 232():113671. PubMed ID: 33338782
[TBL] [Abstract][Full Text] [Related]
18. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
19. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.
Garraud O; Burnouf T
Transfus Clin Biol; 2021 Aug; 28(3):225-227. PubMed ID: 34362557
[No Abstract] [Full Text] [Related]
20. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.
Martin MC; Jimenez A; Ortega N; Parrado A; Page I; Gonzalez MI; Blanco-Peris L
PLoS One; 2022; 17(2):e0264124. PubMed ID: 35202394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
